Boston, MA, July 19, 2016 --(PR.com
)-- Hua Xu, Principal Scientist of Worldwide Medicinal Chemistry at Pfizer, will give a presentation on, “Chemical Biology Tools for Target Identification” at GTCbio’s 11th Drug Design & Medicinal Chemistry to be held on September 12-13, 2016 in Boston, MA
Phenotypic screening is a major source for the discovery of first-in-class small molecule drugs, thanks to its ‘target agnostic’ feature. Recent technology advances and utilization of patient-derived cells have facilitated the design of sophisticated phenotypic assays that recapitulate the disease relevant biology. However, it remains quite challenging to elucidate the mechanism of action and identify the target for compounds of interest from these assays. Dr. Xu will discuss target identification efforts for phenotypic programs by using both probe-based and label-free technologies. These methods would be broadly useful for researchers to identify and validate potential targets for the compounds from phenotypic screens.
This meeting will provide a forum for scientists across multiple disciplines, from both industry and academia, to connect and share complementary perspectives. We will discuss emerging target classes, advances in antibody drug conjugates and other methods for targeted drug delivery, new approaches in flow chemistry, and much more. In addition to scientific presentations, we will have dedicated times for networking among delegates.
Session topics include:
I. Advances in Addressing Traditional and New Target Classes
II. Targeting Protein-Protein Interactions
III. Methods for Target Identification
IV. New Opportunities for Computational Drug Design
V. Big Data in Medicinal Chemistry
For more information, please visit website: https://www.gtcbio.com/conferences/medicinal-chemistry-drug-design-overview
635 W. Foothill Blvd
Monrovia, CA 91016
Phone: (626) 256-6405
Fax: (626) 466-4433